AlphAIAlphAI — Financial news for AI agents
financialcontent.comOCT 202 min read$MYGN

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

Original reporting
financialcontent.com
Published Oct 20, 2026, 2:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why — source image
Source · financialcontent.com
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The cash proceeds and removal of a loss‑making segment improve balance sheet and earnings outlook.

02

Market read

The transaction unlocks value for Myriad, driving a sharp pre‑market rally and may influence peer valuations.

03

What to watch

Potential integration risks for Labcorp and possible regulatory scrutiny of the transaction.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Myriad Genetics has struggled with a declining prenatal division, which weighed on recent guidance.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Shares jumped 22.2% pre‑market after Myriad Genetics agreed to sell its Prenatal Health testing business to Labcorp for $210 million cash.

Expected impact

potential further upside as market prices in the accretive deal

Evidence & confidence

Deal size ($210 M) equals ~52% of market cap and triggered a 22% pre‑market rally; investors view the sale as value‑unlocking.

Market effects

Sector

May prompt other genetic‑testing firms to consider asset sales to improve margins.

Regional

Limited to US biotech/healthcare sector; no broad regional effect.

Global

Highlights consolidation trend in prenatal diagnostics globally.

Counterpoint

What could challenge this read

The sale could signal underlying weakness in Myriad's core business, suggesting caution.

Key entities

  • company
    Myriad Genetics

    US‑listed genetic‑testing firm (ticker MYGN).

  • company
    Labcorp

    US clinical‑laboratory services provider acquiring Myriad's prenatal assets.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 8/10

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

gurufocus.com2 min
OCT 20
$LHMedAI 8/10

Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln

LabCorp (LH) will acquire Myriad Genetics' (MYGN) prenatal testing business for $210M in cash plus inventory value. The deal includes products like Prequel and Foresight. LabCorp expects $160M in revenue the first year and slight earnings accretion. Myriad plans to invest proceeds in cancer care. The transaction is expected to close by early 2027.

rttnews.com2 min